GSK wins FDA green light for chronic hep B treatment Hibsago
GSK's drug Hibsago (bepirovirsen) has been approved by the FDA for chronic hepatitis B treatment, offering a potential functional cure. Approved for use with antiviral therapies, it achieved a 19% functional cure rate in trials. GSK projects peak sales of £2 billion annually, supporting its revenue growth targets. The drug is also under review in other markets.
How this was made
The 30-second read
Why it matters
The approval adds a new revenue stream and could improve GSK's earnings outlook, supporting its target of >£40 bn annual revenue by 2031.
Market read
Regulatory approval of a novel HBV therapy is a high‑impact catalyst for GSK and may influence related biotech stocks.
What to watch
Reimbursement negotiations and competition from existing antivirals may temper revenue expectations.
Background
GSK announced its second major market approval for Hibsago, following Japan approval, positioning the drug as a potential blockbuster in chronic HBV therapy.
Ticker impact
FDA granted approval for GSK's antisense drug Hibsago for chronic hepatitis B, a first US approval for this therapy.
upward pressure as market prices in anticipated sales and market share gains.
FDA approval is a material catalyst for a large pharma; the drug targets a 250 million‑patient market and GSK projects £2 bn annual sales.
Market effects
Boosts the broader hepatitis‑B treatment sector and may spur competitor pipelines.
U.S. biotech and pharma stocks could see a lift on the news.
Highlights FDA's willingness to approve antisense therapies, influencing global drug development outlook.
Counterpoint
If the drug fails to achieve commercial uptake or pricing pressures arise, the rally could be limited.
Key entities
- CompanyGSK
British pharmaceutical giant receiving FDA approval for Hibsago.
- RegulatorFDA
U.S. Food and Drug Administration granting the approval.
